- Home
- ARAY vs PLX Comparison
ARAY vs PLX Comparison
Compare ARAY & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARAY
- PLX
- Stock Information
- Founded
- ARAY 1990
- PLX 1993
- Country
- ARAY United States
- PLX United States
- Employees
- ARAY N/A
- PLX N/A
- Industry
- ARAY Medical/Dental Instruments
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARAY Health Care
- PLX Health Care
- Exchange
- ARAY Nasdaq
- PLX Nasdaq
- Market Cap
- ARAY 170.1M
- PLX 164.2M
- IPO Year
- ARAY 2007
- PLX 1998
- Fundamental
- Price
- ARAY $1.60
- PLX $2.50
- Analyst Decision
- ARAY Strong Buy
- PLX Strong Buy
- Analyst Count
- ARAY 1
- PLX 1
- Target Price
- ARAY $5.00
- PLX $15.00
- AVG Volume (30 Days)
- ARAY 740.8K
- PLX 822.2K
- Earning Date
- ARAY 11-05-2025
- PLX 11-13-2025
- Dividend Yield
- ARAY N/A
- PLX N/A
- EPS Growth
- ARAY N/A
- PLX N/A
- EPS
- ARAY N/A
- PLX 0.08
- Revenue
- ARAY $458,505,000.00
- PLX $61,948,000.00
- Revenue This Year
- ARAY $5.84
- PLX $14.53
- Revenue Next Year
- ARAY $3.90
- PLX $75.77
- P/E Ratio
- ARAY N/A
- PLX $32.28
- Revenue Growth
- ARAY 2.68
- PLX 62.79
- 52 Week Low
- ARAY $1.14
- PLX $0.99
- 52 Week High
- ARAY $2.95
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- ARAY 48.66
- PLX 75.47
- Support Level
- ARAY $1.61
- PLX $1.52
- Resistance Level
- ARAY $1.75
- PLX $2.12
- Average True Range (ATR)
- ARAY 0.09
- PLX 0.12
- MACD
- ARAY -0.01
- PLX 0.05
- Stochastic Oscillator
- ARAY 11.96
- PLX 80.97
About ARAY Accuray Incorporated
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.